THE PREVALENCE OF TAS2R38 GENE PHENOTYPES AMONG THE PATIENTS WITH SOME ENDOCRINE SYSTEM DISORDERS

PTC (phenylthiocarbamide) is one of the focuses of interest from the medical point of view since a number of associations of the taster/nontaster status of PTC sensitivity with various human diseases have been found. It is estimated that ability of sense of PTC bitterness coded by a single gene TAS2R38. The threshold at which people can taste phenylthiocarbamide (PTC) is bimodal, and some people are tasters while, others are nontasters. In recent years, it is actively conducted the studies of genetic markers in various endocrine disorders. Endocrine diseases, particularly thyroid gland prevalence statistics in Georgia is very high. The goal of our research was to study the phenotype of PTC sensitivity among the patients with some endocrine system disorders in the population of Ajara region of Georgia, particularly diabetes type II and different type of goiter (nodular, diffuse etc.) to reveal any correlation between them. A total of 319 individuals including 136 patients with endocrine system and 183 randomly chosen healthy individuals participated in this study. Obtained results shows, that there is an increased incidence of diffuse toxic goiter in individuals with recessive phenotype of TAS2R38 gene and who are unable to taste PTC bitterness. While, PTC sensibility phenotype inclined to develop nodular goiter. Thus PTC- Sensibility phenotype may be considered one of the genetic markers in the forms of Goiter

Hormonal status and distribution of the ABO system phenotypic groups in menopausal and postmenopausal women with breast tumors

93-100Breast cancer is one of the most frequent neoplastic diseases within the female population worldwide. Hormonal imbalance and the ABO system group antigens are among the numerous risk-factors which provoke the development of breast benign and malignant tumors. Here, we have investigated the following sex-steroid hormones: estradiol (E2), progesterone (P), testosterone (T)), non-sex hormones (thyroxin (fT4), thyroid-stimulating hormone (TSH) and prolactin (PRL), and the distribution of the ABO system phenotypic groups in the menopausal and postmenopausal women with breast tumors (benign, malignant). Enzyme-linked immunosorbent assay (ELISA) was used for quantitative determination of hormones. The immune-serological methods were used for investigation of the ABO system phenotypic groups. Our present investigations in menopausal and postmenopausal women with breast tumors have revealed significantly higher expression of sex-steroid hormone estradiol, but decreased progesterone, and also significantly increased testosterone levels. Thyroid gland revealed hypofunction, which confirms the decrease of thyroxin, and increase of prolactin and TSH in the blood. According to our findings, carriers of A(II) phenotypic groups showed high risk for breast tumors development in women during both stages, menopausal and postmenopausal

Hormonal status and distribution of the ABO system phenotypic groups in menopausal and postmenopausal women with breast tumors

Breast cancer is one of the most frequent neoplastic diseases within the female population worldwide. Hormonal imbalance and the ABO system group antigens are among the numerous risk-factors which provoke the development of breast benign and malignant tumors. Here, we have investigated the following sex-steroid hormones: estradiol (E2), progesterone (P), testosterone (T)), non-sex hormones (thyroxin (fT4), thyroid-stimulating hormone (TSH) and prolactin (PRL), and the distribution of the ABO system phenotypic groups in the menopausal and postmenopausal women with breast tumors (benign, malignant). Enzyme-linked immunosorbent assay (ELISA) was used for quantitative determination of hormones. The immune-serological methods were used for investigation of the ABO system phenotypic groups. Our present investigations in menopausal and postmenopausal women with breast tumors have revealed significantly higher expression of sex-steroid hormone estradiol, but decreased progesterone, and also significantly increased testosterone levels. Thyroid gland revealed hypofunction, which confirms the decrease of thyroxin, and increase of prolactin and TSH in the blood. According to our findings, carriers of A(II) phenotypic groups showed high risk for breast tumors development in women during both stages, menopausal and postmenopausal